Back to search

Article

Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemia

2025-02-19

Abstract excerpt

<title>Abstract</title> <p>Objective This study aims to develop a clinical prediction model for sensitivity to Bcl-2 inhibitors combined with hypomethylating agents (HMAs) in elderly/unfit patients with acute myeloid leukemia (AML). Methods Clinical data, including French-American-British (FAB) classification, chromosomal karyotype, and second-generation sequencing results, were retrospectively collected from c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
facd179d-388d-5825-a85c-ddf53d18dff0
DOI
10.21203/rs.3.rs-5949741/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Development of a clinical prediction model for sensitivity to combination therapy of Bcl-2 inhibitors and hypomethylating agents in elderly/unfit patients with acute myeloid leukemiaDOI 10.21203/rs.3.rs-5949741/v1
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxSemantic proximity
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity
An Ensemble Model for Acute Myeloid Leukemia Risk Stratification Recommendations by Combining Machine Learning with Clinical GuidelinesSemantic proximity
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Semantic proximity
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Semantic proximity
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort.Semantic proximity
Prediction of survival with intensive chemotherapy in acute myeloid leukemia.Semantic proximity
Characteristics, outcomes and treatment patterns in acute myeloid leukemia patients 60 Years or older in Colombia: a RENEHOC-PETHEMA studySemantic proximity
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity.Semantic proximity
A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus VenetoclaxSemantic proximity
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.Semantic proximity
Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity
Select a neighboring publication to make it the new centre.